Orwell, G., Animal Farm: A Fairy Story (New York: Signet Classics, 2016).Google Scholar

Baker, J.B., “Vertical Restraints with Horizontal Consequences: Competitive Effects of Most Favored-Customer Clauses,” Speech before Business Development Associates, Inc. 1996 Antitrust Confernce, Washington, D.C., Sept. 28, 1995, available at <https://www.ftc.gov/public-statements/1995/09/vertical-restraints-horizontal-consequences-competitiveeffects-most> (last visited November 1, 2018).+(last+visited+November+1,+2018).>Google Scholar

See Greaney, T.L. and Richman, B.D., “Delivering and Paying for Healthcare Services: Priorities for Competition in Critical Markets,” American Antitrust Institute White Paper, May 2018.Google Scholar

FTC v. Advocate Health Care Network, 841 F.3d 460 (7th Cir. 2016); FTC v. Penn State Hershey Med. Ctr., 838 F.3d 327 (3d Cir. 2016); ProMedica Health Sys., Inc. v. FTC, 749 F.3d 559, 571 (6th Cir. 2014).Google Scholar

Saint Alphonsus Medical Center-Nampa & FTC v. St. Luke's Health System, 778 F.3d 775, 793 (9th Cir. 2015); FTC and North Dakota v. Sanford Health, Case No. 1;17-cv-00133 (D.N.D. Dec. 15, 2017). See also In the Matter of Renown Health, FED. TRADE COMM’N. C-4366 (Dec. 4, 2012) (consent order).Google Scholar

U.S. v. Anthem, Inc., 855 F. 3d 345 (D.C. Cir. 2017); United States v. Aetna, Inc., 240 F. Supp. 3d 1 (D.D.C. 2017).Google Scholar

See Greaney and Richman, supra note 3.Google Scholar

Greaney, T.L., “The Affordable Care Act and Competition Policy: Antidote or Placebo?” Oregon Law Review 89, no. 3 (2011): 811–845.Google Scholar

See Casalino, L. P., “The Medicare Access and CHIP Reauthorization Act and the Corporate Transformation of American Medicine,” Health Affairs 36, no. 5 (2017): 865–869.Google Scholar

See Gamble, M., “The Quiet Takeover: Insurers Buying Physicians and Hospitals,” Beckers Hospital Review (2011), available at <https://www.beckershospitalreview.com/hospital-management-administration/the-quiet-takeover-insurers-buying-physicians-and-hospitals.html> (last visited November 1, 2018); R. Abelson, “As Health Care Changes, Insurers, Hospitals and Drugstores Team Up,” New York Times, November 26, 2017.+(last+visited+November+1,+2018);+R.+Abelson,+“As+Health+Care+Changes,+Insurers,+Hospitals+and+Drugstores+Team+Up,”+New+York+Times,+November+26,+2017.>Google Scholar

Abelson, R., “UnitedHealth Group to Buy Outpatient Surgery Chain for $2.3 Billion,” New York Times, Jan. 9, 2017.Google Scholar

Abelson, R., “UnitedHealth Buys Large Doctors Group as Lines Blur in Health Care,” New York Times, December 6, 2017.Google Scholar

Mathews, A.W., “UnitedHealth to Buy Large Doctor Group for $4.9 Billion,” Wall Street Journal, December 6, 2017.Google Scholar

See Leibenluft, R. F., “Antitrust and Provider Collaborations: Where We’ve Been and What Should Be Done Now,” Journal of Health Politics, Policy & Law 40, no. 4 (2015): 847–874.Google Scholar

Berenson, R.A., Ginsburg, P.B., Christianson, J.B., and Yee, T., “The Growing Power of Some Providers to Win Steep Increases in Payment from Insurers Suggest Policy Remedies Are Needed,” Health Affairs 31, no. 5 (2012): 973–981.Google Scholar

U.S. v. AT&T, 2017 WL 6329012 (D.D.C 2018).Google Scholar

United States v. Hammermill Paper Co., 429 F. Supp. 1271 (W.D. Pa. 1977).Google Scholar

The Non-Horizontal Merger Guidelines, issued in 1992 and revised in 1997, have received little attention in the courts and focus on harms from reducing the probability of entry and facilitating collusion; notably, the term “foreclosure” does not appear in the Guidelines. U.S. Department of Justice, Non-Horizontal Merger Guidelines, available at <https://www.justice.gov/atr/non-horizontal-merger-guidelines> (last visited November 1, 2018).+(last+visited+November+1,+2018).>Google Scholar

Ford Motor Co. v. United States, 405 U.S. 562 (1972).Google Scholar

The FTC's first challenge to a physician merger, commenced in 2012, involved the acquisitions by the largest hospital system in the Reno, Nevada area of two cardiology groups — making the system the employer of 88% of the active cardiologists in the market. The FTC entered into a consent order that did not enjoin the merger but rather required the system to release physicians from covenants not to compete. In the Matter of Renown Health, FTC Dkt. No. Docket No. C-4366 (December 4, 2012), available at <www.ftc.gov/enforcement/cases-proceedings/1110101/renown-health-matter> (last visited November 1, 2018). (last visited November 1, 2018).' href=https://scholar.google.com/scholar?q=The+FTC's+first+challenge+to+a+physician+merger,+commenced+in+2012,+involved+the+acquisitions+by+the+largest+hospital+system+in+the+Reno,+Nevada+area+of+two+cardiology+groups+—+making+the+system+the+employer+of+88%+of+the+active+cardiologists+in+the+market.+The+FTC+entered+into+a+consent+order+that+did+not+enjoin+the+merger+but+rather+required+the+system+to+release+physicians+from+covenants+not+to+compete.+In+the+Matter+of+Renown+Health,+FTC+Dkt.+No.+Docket+No.+C-4366+(December+4,+2012),+available+at++(last+visited+November+1,+2018).>Google Scholar

Saint Alphonsus Med. Ctr.-Nampa Inc. v. St. Luke's Health Sys., Ltd., 778 F.3d 775, 791(9th Cir. 2015).Google Scholar

See Greaney, T. L. and Ross, D., “Navigating Through the Fog of Vertical Merger Law: A Guide to Counselling Hospital Physician Consolidation,” University of Washington Law Review 91, no. 1 (2016): 199–251 at 221-222.Google Scholar

See, J. Baker, supra note 2 (comparing the broad brush antitrust maxim, “vertical good, horizontal bad” to Snowball's “four legs good, two legs bad” in George Orwell's Animal Farm).Google Scholar

Herbert Hovenkamp described Robert Bork's “beguingly simple” account of the competitive effects of vertical mergers as follows: First, if vertical integration created efficiencies, then a vertically integrated firm would have cost advantages over unintegrated rivals. In that case vertical integration would deter unintegrated entry, but it is not antitrust's purpose to condemn cost savings. Second, if vertical integration did not create any efficiencies, then it would not impede entry by anyone. Firms that wished to enter at one stage alone could contract with firms at the other stage and be just as efficient as the vertically integrated firm. Third, if vertical integration resulted in higher costs, then vertically integrated firms would decline in favor of unintegrated firms. Fourth, in competitively structured markets vertical integration would lead to self-dealing, but that would do no more than force realignment in purchasing and sale patterns. Bork's observations were built on an extraordinarily narrow conception of entry barriers. He barely mentioned patents or other intellectual property rights. There was no conception that sunk costs plus risk could facilitate entry deterrence. Hovenkamp, H., “Robert Bork and Vertical Integration: Leverage, Foreclosure, and Efficiency,” Antitrust Law Journal 79, no. 3 (2014): 983–1001.Google Scholar

Bork, R. H., The Antitrust Paradox (New York: Basic Books, 1978): at 225.Google Scholar

See, Goldsmith, J., Burns, L.R., Sen, A., and Goldmith, T., Integrated Delivery Network: In Search of Benefit and Market Effects (National Academy of Social Insurance, 2015): at 8; Advocates for a permissive standard governing mergers also assert that alternative arrangements that enable vertical relations such as joint ventures and other contractual commitments are less efficient because of the uncertainties inherent in contracting and transaction costs. See B. Klein, R. G. Crawford, and A. A. Alchian, “Vertical Integration, Appropriable Rents, and the Competitive Contracting Process,” Journal of Law and Economics 21, no. 2 (1978): 297-235 at 298.Google Scholar

Krattenmaker, T. G. and Salop, S. C., “Anticompetitive Exclusion: Raising Rivals Costs to Achieve Power Over Price,” Yale Law Journal 96, no. 2 (1986): 209–293 at 213.Google Scholar

Professor Salop's recent work systematically refutes the bases upon which Chicago School's permissive approach to vertical mergers is based. Salop, S. C., “Invigorating Vertical Merger Enforcement,” Yale Law Journal 127, no. 7 (2018): 1962–1964. Other scholars have also criticized the law's neglect of competitive harms from vertical arrangements. See e.g., Baker, J.B., “Exclusion as a Core Competition Concern,” Antitrust Law Journal 78, no. 3 (2013): 527–589.Google Scholar

Salop, S. C. and Culley, D. P., “Potential Competitive Effects of Vertical Mergers: A How-To Guide for Practitioners,” December 8, 2014, available at <http://scholarship.law.georgetown.edu/cgi/viewcontent.cgi?article=2404&context=facpub> (“Vertical mergers seldom involve firms that have monopolies protected by prohibitive entry barriers. If there is no monopoly, then there is no single monopoly profit.”)+(“Vertical+mergers+seldom+involve+firms+that+have+monopolies+protected+by+prohibitive+entry+barriers.+If+there+is+no+monopoly,+then+there+is+no+single+monopoly+profit.”)>Google Scholar

See Salop and Culley, supra note 30 and Salop, “Invigorating Vertical Merger Enforcement” supra note 29.Google Scholar

For example, vertical mergers may facilitate coordination in the hospital market by weakening the disruptive behavior of a nonintegrated hospital, a strategy that could be implemented with targeted input foreclosure or threats of foreclosure. See, Salop and Culley supra note 30 at 25-26.Google Scholar

In 2008 the FTC challenged a ten year, exclusive sublicense for Venofer, a pharmaceutical product produced by Daiichi Sankyo used by dialysis clinics operated by Fresenius Medical Care, which would allow Fresnius to evade Medicare price regulations. In the Matter of Fresenius Medical Care AG & Co. KGaA and Daiichi Sankyo Company, Ltd, No. 081-0146 (F.T.C. Sept. 15, 2008), available at <www.ftc.gov/sites/default/files/documents/cases/2008/09/080915freseniusanal.pdf> (last visited November 1, 2018).+(last+visited+November+1,+2018).>Google Scholar

See generally, Greaney and Ross, supra note 23; see also Declaration of Debra Hass-Wilson in St. Alphonsus Med. Center-Nampa et al. v. St. Luke's Health 2012 WL 9515607 (D.Idaho) (economic analysis of foreclosure effects in hospital acquisition of a primary care physician practice).Google Scholar

Letter from D. Jones, Commissioner, California Department of Insurance to Attorney General Jeff Sessions and Assistant Attorney General Makan Delrahim, U.S. Dep’t of Justice (August 1, 2018); Letter from J. L. Madara, Executive Vice President and CEO, American Medical Association to Assistant Attorney General Makan Delrahim (August 7, 2018); Letter from D. L. Moss, President, American Antitrust Division to Makan Delrahim, Assistant Attorney General, Antitrust Division, U.S. Department of Justice (March 2017), available at <https://www.antitrustinstitute.org/work-product/aai-calls-on-doj-to-block-the-merger-of-cvs-aetna-vertical-integration-will-restructure-important-healthcare-markets-to-the-detriment-of-competition-and-consumers> (last visited December 10, 2018). See also, Statement of T. L. Greaney, California Department of Insurance Hearing on Proposed CVS/Aetna Merger (June 19, 2018).+(last+visited+December+10,+2018).+See+also,+Statement+of+T.+L.+Greaney,+California+Department+of+Insurance+Hearing+on+Proposed+CVS/Aetna+Merger+(June+19,+2018).>Google Scholar

Id.Google Scholar

Id.Google Scholar

See notes 43-46 infra.Google Scholar

See Madara Letter supra note 35; Greaney Statement supra note 35.Google Scholar

“Cigna/Express Scripts: Coordinated PBM Impact on Health Plan Rivals Tops Potential Vertical Concerns,” The Capitol Forum 6, no. 165, April 23, 2018.Google Scholar

Salop supra note 29 at 1975-1980.Google Scholar

Id. See also, Greaney and Ross, supra note 23.Google Scholar

American Medical Association, Competition in Health Insurance: A Comprehensive Study of U.S. Markets (2017).Google Scholar

Gaynor, M., “Examining the Impact of Health Care Consolidation,” Statement before the Energy and Commerce Oversight Committee, U.S. House of Representatives, February 14, 2018, at 7.Google Scholar

Dafny, L., “Health Insurance Industry Consolidation: What Do We Know From the Past, Is It Relevant in Light of the ACA, and What Should We Ask?” Testimony Before the Subcomm. on Antitrust, Competition Policy, and Consumer Rights of the S. Comm. on the Judiciary, 114 Cong. 5 (2015) available at <http://www.judiciary.senate.gov/imo/media/doc/09-22-15%20Dafny%20Testimony%20Updated.pdf> (last visited November 2, 2018).+(last+visited+November+2,+2018).>Google Scholar

Id.Google Scholar

Fulton, B. D., “Health Insurance Market Concentration in the United States: Trends in the United States and Policy Responses,” Health Affairs 36, no. 9 (2017): 1530–1538.Google Scholar

Id.Google Scholar

Stern, C., “CVS and Walgreens are Completely Dominating U.S. Drugstore Industry,” Business Insider, July 29, 2015.Google Scholar

Fulton, supra note 47.Google Scholar

Gaynor, supra note 44 at 6.Google Scholar

Id.; see also Dafny, Health Care Consolidation, supra note 45.Google Scholar

See generally id. at 7-9; See also Gaynor, M. and Town, R. J., “The Impact of Hospital Consolidation,” (2012) The Synthesis Project, Policy Brief No. 9, Robert Wood Johnson Foundation (hospitals); see also note 56 infra (physicians).Google Scholar

See Gaynor, supra note 44 at 10-11.Google Scholar

See Havighurst, C. C. and Richman, B. D., “The Provider Monopoly Problem in Health Care,” Oregon Law Review 89 (2011): 847–883; Greaney supra note 8.Google Scholar

Goldsmith, J., Burns, L. R., Sen, A., and Goldsmith, T., Integrated Delivery Networks: In Search of Benefits and Market Effects, National Academy of Social Insurance (2015)(summarizing literature and analyzing performance of 15 of the largest integrated delivery systems).Google Scholar

See e.g., McWilliams, J. M. et al., “Delivery System Integration and Spending and Quality for Medicare Beneficiaries,” JAMA 173, no. 15 (2013): 1447–1456.Google Scholar

See Salop, Invigorating Vertical Merger Enforcement, supra note 29 at 1973 (“the same inherent upward pricing pressure occurs for vertical mergers” as for horizontal mergers).Google Scholar

Gaynor, M., “Examining the Impact of Health Care Consolidation,” Statement before the Energy and Commerce Oversight Committee, U.S. House of Representatives, February 14, 2018, at 11.Google Scholar

See, e.g., Stuckey, J. and White, D., “When and When Not to Vertically Integrate,” McKinsey Quarterly, August 1993, available at <https://www.mckinsey.com/business-functions/strategy-and-corporate-finance/our-insights/when-and-when-not-to-vertically-integrate> (last visited November 2, 2018); Salop, Invigorating Vertical Merger Enforcement, supra note 29.+(last+visited+November+2,+2018);+Salop,+Invigorating+Vertical+Merger+Enforcement,+supra+note+29.>Google Scholar

See Gaynor, supra note 59.Google Scholar

Baker, L.C., Bundorf, M. K., and Kessler, D. P., “Vertical Integration: Hospital Ownership of Physician Practices Is Associated with Higher Prices and Spending,” Health Affairs 33, no. 5 (2014): 756–763 at 762; D. Haas-Wilson, “Hospital-Physician Integration: The St. Luke's Case,” in The Antitrust Revolution: Economics, Competition and Policy (Kwoka ed., forthcoming); J. Robinson and K. Miller, “Total Expenditures per Patient in Hospital-Owned and Physician-Owned Physician Organizations in California,” JAMA 312, no. 16 (2014): 1663-1669(finding hospital-owned physician organizations had 10-20% higher total expenditures/patient than physician-owned organizations); C. Capps, D. Dranove, and C. Ody, “The Effect of Hospital Acquisitions of Physician Practices on Prices and Spending,” Institute for Policy Research, Northwestern University, Working Paper No. WP-15-02, Feb. 2015 (finding that vertical integration was associated with a 13.7% increase in physician prices); and H. T. Neprash et al., “Association of Financial Integration Between Physicians and Hospitals With Commercial Health Care Prices,” JAMA Internal Medicine 175, no. 12 (2015): 1932-1939 (finding that MSAs with increases in physician-hospital integration experienced median price increases of $75). A. Dunn and A.H. Shapiro, “Do Physicians Possess Market Power?” Journal of Law and Economics 57, no. 1 (2014): 159-193. R. Kocher and N. Sahni, “Hospitals’ Race to Employ Physicians — The Logic behind a Money-Losing Proposition,” New England Journal of Medicine 363, no. 19 (2012): 1790-1793.Google Scholar

Scheffler, R., “What Happens When Hospitals Buy Physician Practices in California: Impacts on ACA Premiums and Out-patient Prices,” Health Affairs (forthcoming 2018).Google Scholar

Berenson, R.A., “A Physician's Perspective on Vertical Integration,” Health Affairs 36, no. 9 (2017): 1585–1590 at 1586 (“literature reviews find integration has not improved quality and could even reduce it because of reduced competition”).Google Scholar

Dafny, L. S. and Lee, T. H., “The Good Merger” New England Journal of Medicine 372, no. 22 (2015): 2077–2079.Google Scholar

See Greaney and Richman, supra note 3.Google Scholar

Dranove, D. and Ody, C., “Employed for Higher Pay? How Medicare Facility Fees Affect Hospital Employment of Physicians,” Kellogg Faculty Publications (2016), available at <http://www.kellogg.northwestern.edu/faculty/publication_detail.aspx?id=be3b359c-e31a-11e6-9fbb-0050569b3e41> (last visited November 2, 2018).+(last+visited+November+2,+2018).>Google Scholar

Desai, S. and McWilliams, J. M., “Consequences of the 340B Drug Pricing Program.” New England Journal of Medicine 378, no. 6 (2018): 539–548.CrossRefGoogle Scholar

Robert Wood Johnson Foundation, “Health Policy Brief: Site-Neutral Payments,” Health Affairs, July 24, 2014, MedPAC, Report to Congress 2014.Google Scholar

See 42 C.F.R. 411.357 (Stark Law exception allowing physician with bona fide employment relationship to make referrals to employer-hospital subject to certain conditions).Google Scholar

U.S. v. Blue Cross and Blue Shield of Michigan, 809 F. Supp. 665 (E.D. Mich. 2011).Google Scholar

See U.S. and North Carolina v. Charlotte-Mecklenburg Hospital Authority, d/b/a Carolinas Healthcare System, March 30, 2017 (Order denying defendant's motion for judgment on the pleadings).Google Scholar

California v. Sutter Health, CGC-18-565398 (San Francisco County Superior Court) (Mar. 29, 2018).Google Scholar

See Feldman, R. and Frondorf, E., Drug Wars: How Big Pharma Raises Prices and Keeps Generics Off the Market (New York, Cambridge University Press, 2017).Google Scholar

See Verizon Communications Inc. v. Law Offices of Curtis V. Trinko, 124 S. ct. 872 (2004); see also, Greaney, T.L., “Coping with Concentration,” Health Affairs 36, No.9 (2017): 1564–1571.Google Scholar

Baker, J.B., “Exclusion as a Core Competition Concern,” Antitrust Law Journal 78, no. 3 (2013): 527–589.Google Scholar

Hovenkamp, H., “Prophylactic Merger Policy,” University of California Hastings Law Journal (forthcoming 2018).Google Scholar

See Id. (discussing the application of the incipiency test in the case of vertical mergers).Google Scholar

See e.g. Saint Alphonsus Med. Ctr.-Nampa Inc. v. St. Luke's Health Sys., Ltd., 778 F.3d 775, 791(9th Cir. 2015); U.S. v. Anthem, Inc., 855 F. 3d 345 (D.C. Cir. 2017).Google Scholar

U.S. Department of Justice and Federal Trade Commission, Horizontal Merger Guidelines, (2010) §9.Google Scholar

Animal Farm, supra note 1. (“The creatures outside looked from pig to man, and from man to pig, and from pig to man again; but already it was impossible to say which was which.”)Google Scholar